Why 🎵 music labels is unique business model ? @NeilBahal
Watch the video !
Link :
1. High Entry Barriers
It's not easy to create catalogue of 1 Lk songs in short time. Each movie will have 4-5 songs and in a year about 100 movies might be released,
so about 500 songs will be produced in a year. To create catalogue of 25000 songs it will need 50 years. Industry will keep consolidating, as bigger players will acquire the smaller music labels.
2. Get the acquisition costs recovered in 3-5 years and keep the content with you for lifetime without any incremental costs.
Keyword : Without incremental costs
3. Value migration from ad-based music to paid music
Ad-based music listeners are about 7x of paid premium music listeners while revenues from them are 22x more compared to ad-based revenues. This is the data of international market. In India opportunity size much higher !
4. Mobile phone users in India & Cost of 1 GB Data in world in $
1. Revenues for the quarter stood at ₹428.4Cr, up 104% from same period previous year
2. EBITDA stood at ₹46.7 Cr translating to EBITDA margins of 10.9%
3. PAT stood at ₹22.5 Cr with PAT margins of 5.3%
4. Undertaking price hikes wherever possible to offset these raw material pressures.
5. This is the first full quarter of consolidation of recent acquisitions of Unitop and Tristar in Rossari’s performance. Both these companies delivered growth during the period, which assisted overall performance.
1. They were the fastest growing company among the Top 30 companies in the domestic formulations market as per IQVIA. JB grew at 27% vs market growth of 18%.
2. Revenues for the quarter stood at ₹601 Cr (10% growth YoY).
3. EBITDA excluding ESOP cost stood at ₹153 Cr (10.5% decline YoY). Gross margins for the quarter stood at 66% although there was significant cost inflation.
4. Cost pressure persists on raw material and packing material, which is expected to continue in the medium-term.
5. During Q3 FY22, Domestic Formulations business launched 12 new products including Molnupiravir, Cilacar TM, Azovas-T and Pirfenidone.
Watch the video to understand the business details :
1. Revenues for the quarter stood at ₹358 Cr (4.8% growth YoY).
2. Growth was mainly driven by the Formulations business which grew at 18.5% YoY on a constant currency basis whereas the API business declined by 20% YoY driven by logistic challenges and subdued demand for Albendazole.
3. Growth in the API portfolio excluding Albendazole has been strong in the first 9 months. Albendazole demand still remains subdued but there is a strong recovery in demand QoQ.
1. The revenues for Q3FY22 stood at ₹429.4Cr from ₹310.3 Cr in same period previous year accounting to growth of 38.4% YoY
2. EBITDA for the quarter stood at ₹48.5Cr translating to EBITDA margins of 11.29%
3. The contributors to Consolidated Net Profit after tax of ₹106.02Crore in Q3-FY22 include share of profit of DyStar (associate company of Kiri) to the tune of ₹81.49 Crore, and
₹13.44Crore from Lonsen Kiri Chemical Industries Limited
3. Consolidated Gross Margin has strengthened to 33%, a Q-o-Q increase of 3% which is further expected to improve in coming quarters
1. For Q3FY22 revenue was ₹185.8 Cr vs ₹130.4 Cr in Q3FY21 a growth of 42% on YoY basis.
2. Q3 EBITDA was at ₹30.2 Cr as compared to ₹27.3 Cr in the same quarter of the previous year.
3. For 9M FY22 revenue was ₹446.6 Cr vs ₹330.8 Cr in 9MFY21 a growth of 35% on YoY basis.
4. 9MFY22 EBITDA surged by 141% to ₹79.7 Cr as compared to ₹33.1 Cr in 9MFY21.
5. Esports segment recorded revenue of ₹109.3 Cr in Q3FY22 vs ₹57.8 Cr last year in the same quarter, a growth of 89% YoY basis.
Their Gamified early learning segment recorded revenue of ₹47.2Cr.
1. Operating revenue for Q3FY22 was ₹18.3 million compared to ₹11.2 in Q2FY22.
2. Net loss for the Quarter was at ₹29.9 million mainly because of Esop.
3. Portfolio value of investments increased from ₹436.3 million on December 31, 2020 to ₹611.2 million on December 31, 2021.
Business Update
1. Signal Analytics, a wholly owned subsidiary raised ₹52.4 million by way of preferential allotment of Pre Series A. Thereby Xelpmoc shareholding in Signal has changed to 91.95% on a fully diluted basis.